Log in to save to my catalogue

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of...

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fa3f18a7c5a247f2bb673138b510d84e

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

About this item

Full title

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Publisher

London, England: SAGE Publications

Journal title

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211019675-17588359211019675

Language

English

Formats

Publication information

Publisher

London, England: SAGE Publications

More information

Scope and Contents

Contents

Introduction:
Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown.
Methods:
A retrospective efficacy and safety a...

Alternative Titles

Full title

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_fa3f18a7c5a247f2bb673138b510d84e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fa3f18a7c5a247f2bb673138b510d84e

Other Identifiers

ISSN

1758-8359,1758-8340

E-ISSN

1758-8359

DOI

10.1177/17588359211019675